Literature DB >> 23458477

Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.

Biku J John1, Prashant Naik, Alastair Ironside, Brian R Davidson, Guiseppe Fusai, Roopinder Gillmore, Jennifer Watkins, Sakhawat H Rahman.   

Abstract

INTRODUCTION: The presence of positive nodal disease (LND) and the number of lymph nodes involved (LNB) are known to be significant prognostic markers for resected adenocarcinoma of the pancreas. In addition, the ratio of the number of involved nodes to the number of nodes resected known as the lymph node ratio (LNR) is emerging as an important prognostic marker. The role of the resection margin (RM) as presently defined (R1 ≤ 1 mm) is unclear as results differ based on the dataset. The aim of this study was to assess the impact of nodal disease and a redefined RM on outcome.
MATERIAL AND METHODS: Retrospective analysis of pancreatic head resections for adenocarcinomas from 2003-2009. The RM was re-analysed based on tumour clearance and categorized into: histopathological evidence of a tumour; ≤ 0.5 mm, ≤ 1 mm, ≤ 1.5 mm, or ≤ 2.0 mm of the actual surgical resection margin. The impact of histopathological variables on cancer-specific survival (CSS) and disease-free survival (DFS) was analysed.
RESULTS: LND, LNB and LNR were independent prognostic markers for CSS (P = 0.048, 0.003, 0.016) but, did not influence DFS. A LNR < 0.143 was associated with a higher CSS [38.16 ± 4.69 versus 20.59 ± 2.20 months, P = 0.0042, hazard ratio (HR) 3.74 (95% confidence interval (CI) 1.52-9.23)]. An R1 RM was not associated with CSS or DFS on multivariate analysis, irrespective of the distance. LNB and LNR maintained independent significance irrespective of the size of the RM.
CONCLUSION: LNB and LNR are the only prognostic factors for CSS in patients with pancreatic head adenocarcinoma, but do not predict recurrence. Microscopic RMs does not seem to influence the outcome even when redefined. Further prospective studies are indicated to substantiate these findings.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2013        PMID: 23458477      PMCID: PMC3948534          DOI: 10.1111/hpb.12019

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  36 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Authors:  J P Neoptolemos; J A Dunn; D D Stocken; J Almond; K Link; H Beger; C Bassi; M Falconi; P Pederzoli; C Dervenis; L Fernandez-Cruz; F Lacaine; A Pap; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Lancet       Date:  2001-11-10       Impact factor: 79.321

4.  Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Authors:  T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans
Journal:  Ann Surg Oncol       Date:  2001-03       Impact factor: 5.344

5.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

6.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

7.  Pancreaticoduodenectomy: a 20-year experience in 516 patients.

Authors:  C Max Schmidt; Emilie S Powell; Constantin T Yiannoutsos; Thomas J Howard; Eric A Wiebke; Chad A Wiesenauer; Joel A Baumgardner; Oscar W Cummings; Lewis E Jacobson; Thomas A Broadie; David F Canal; Robert J Goulet; Eardie A Curie; Higinia Cardenes; John M Watkins; Patrick J Loehrer; Keith D Lillemoe; James A Madura
Journal:  Arch Surg       Date:  2004-07

8.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

9.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin.

Authors:  Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

View more
  13 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 2.  [R1 resection for pancreatic carcinoma].

Authors:  G F Weber; S Kersting; F Haller; R Grützmann
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

3.  A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer.

Authors:  Toshiro Masuda; Amanda M Dann; Irmina A Elliott; Hideo Baba; Stephen Kim; Alireza Sedarat; V Raman Muthusamy; Mark D Girgis; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2017-10-17       Impact factor: 3.452

Review 4.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

Authors:  M Elshaer; G Gravante; M Kosmin; A Riaz; A Al-Bahrani
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

5.  The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Takeo Nitta; Toru Nakamura; Tomoko Mitsuhashi; Toshimichi Asano; Keisuke Okamura; Takahiro Tsuchikawa; Eiji Tamoto; Soichi Murakami; Takehiro Noji; Yo Kurashima; Yuma Ebihara; Yoshitsugu Nakanishi; Toshiaki Shichinohe; Satoshi Hirano
Journal:  Surg Today       Date:  2016-09-27       Impact factor: 2.549

6.  Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.

Authors:  Emre Koca; Taha Y Kuzan; Omer Dizdar; Taner Babacan; Ilyas Sahin; Erhan Ararat; Kadri Altundag
Journal:  Med Oncol       Date:  2013-06-01       Impact factor: 3.064

7.  Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.

Authors:  Sung Jun Ma; Gregory M Hermann; Kavitha M Prezzano; Lucas M Serra; Austin J Iovoli; Anurag K Singh
Journal:  Cancer Med       Date:  2019-01-16       Impact factor: 4.452

8.  Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.

Authors:  Chang Moo Kang; Sung Hwan Lee; Ho Kyoung Hwang; Mijin Yun; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy.

Authors:  Chaobin He; Yize Mao; Jun Wang; Fangting Duan; Xiaojun Lin; Shengping Li
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

10.  Pathomorphological features of metastatic lymph nodes as predictors of postoperative prognosis in pancreatic cancer.

Authors:  Mayumi Hoshikawa; Sho Ogata; Makoto Nishikawa; Akifumi Kimura; Takahiro Einama; Takuji Noro; Suefumi Aosasa; Kazuo Hase; Hironori Tsujimoto; Hideki Ueno; Junji Yamamoto
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.